Clinical trials: Overall Survival of Patients With Gastric Cancer
Gastric Cancer, Gastroesophageal Cancer
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in…
- Trial name
- GASTRANOX (NCT00718354)
- Testing
- Enoxaparin, Standard Chemotherapy
- Where
- 15 sites in India
- Volunteers
- 740 people
- Sponsor
- Thrombosis Research Institute
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer
Second-line chemotherapy represents an option in gastric cancer, especially for patients with adequate performance status. Two randomized phase III trials comparing 2nd-line docetaxel with best-supportive care have reported a…
- Trial name
- MICADO (NCT02007148)
- Testing
- capecitabine, Docetaxel
- Where
- 2 sites in Italy
- Volunteers
- 51 people
- Sponsor
- International Group of Endovascular Oncology
Gastric Cancer
Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
The purpose of this study is to evaluate the efficacy and tolerability of the combination of epirubicin, oxaliplatin and 5-day continuous infusional 5-fluorouracil (EOF5 regimen) in patients with unresectable advanced or…
- Trial name
- NCT00767377
- Testing
- EOF5
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Fudan University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Gastric Cancer
Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
The purpose of this study is to evaluate the efficacy and overall survival of the regimen of XELOX (Xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.
- Trial name
- NCT00568529
- Testing
- Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Gastric Cancer
Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer…
- Trial name
- NCT00595972
- Testing
- ECF-endostar
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Gastric Cancer
Study of Cetuximab to Treat Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of cetuximab combined with FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy
- Trial name
- STAGE (NCT00699881)
- Testing
- cetuximab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
Gastric Cancer, Pancreas Cancer
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
This prospective, randomized, open-label and multicenter phase III study is aimed to estimate the survival benefit of Early Palliative Care (EPC) combined with standard oncology care including first-line chemotherapy…
- Conditions
- Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer
- Trial name
- EPIC-1511 (NCT02853474)
- Testing
- Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
- Where
- 20 sites in France
- Volunteers
- 480 people
- Sponsor
- Centre Oscar Lambret
Gastric Cancer, Mortality of Gastric Cancer
Predictive Factors of Morbidity and Mortality and Overall Survival of Patients With Gastric Cancer : a Case Series
This is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the IBN ROCHD University Hospital…
- Conditions
- Gastric Cancer, Mortality of Gastric Cancer, Overall Survival of Patients With Gastric Cancer
- Trial name
- NCT05186402
- Testing
- Total or subtotal gastrectomy
- Volunteers
- 80 people
- Sponsor
- Sylvestre KABURA
Gastric Cancer
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with…
- Trial name
- NCT01041404
- Testing
- Trastuzumab, Fluorouracil, Cisplatin
- Where
- 142 sites in Australia, Belgium and 22 more
- Volunteers
- 584 people
- Sponsor
- Hoffmann-La Roche
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Gastric Cancer
CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
The goal of this prospective observational study is to evaluate how well a previously developed prediction model can estimate outcomes in adults with gastric cancer.
- Trial name
- NCT07776067
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of sorafenib as second line treatment in patients with Advanced or Metastatic Gastric Cancer (A/MGC).
- Trial name
- NCT00595985
- Testing
- sorafenib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Fudan University